biostudies-literatureUnknown39(5)Burnett ALAstellas Pharma Global Development, Inc.Astellas Pharma Global Development<h4>Aims</h4>To characterize the epidemiology and treatment patterns of adult men (≥40 years) diagnosed with, or treated for, overactive bladder (OAB) and/or benign prostatic hyperplasia (BPH).<h4>Methods</h4>This retrospective observational study used data extracted from the IBM MarketScan Commercial Claims and Encounters database and the Medicare Supplemental Coordination of Benefits database. Men with BPH and/or OAB were identified and observed to assess treatment and diagnostic patterns.<h4>Results</h4>Within the entire study sample (N = 462 400), BPH diagnosis (61.5%) and BPH treatment (73.7%) were more common than the corresponding values for OAB (25.8% and 7.0%, respectively). Notably, among diagnosed individuals, the dispensation of a corresponding treatment was more likely in indiNeurourology and urodynamics1378-1386https://www.ebi.ac.uk/biostudies/studies/S-EPMC7384148biostudies-literatureUndertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: A retrospective observational study.PMC7384148Nimke DWalker DRJohnston KMHairston JCBurnett ALFeng QLozano-Ortega GfalseUndertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: A retrospective observational study.<h4>Aims</h4>To characterize the epidemiology and treatment patterns of adult men (≥40 years) diagnosed with, or treated for, overactive bladder (OAB) and/or benign prostatic hyperplasia (BPH).<h4>Methods</h4>This retrospective observational study used data extracted from the IBM MarketScan Commercial Claims and Encounters database and the Medicare Supplemental Coordination of Benefits database. Men with BPH and/or OAB were identified and observed to assess treatment and diagnostic patterns.<h4>Results</h4>Within the entire study sample (N = 462 400), BPH diagnosis (61.5%) and BPH treatment (73.7%) were more common than the corresponding values for OAB (25.8% and 7.0%, respectively). Notably, among diagnosed individuals, the dispensation of a corresponding treatment was more likely in indi2020-01-01T00:00:00Z2020 Jun2025-04-19T23:03:13.563Z2025-04-19T23:03:13.563ZS-EPMC73841483238353310.1002/nau.24348